General American Investors Co. Inc. Buys 1,448,907 Shares of Maravai LifeSciences Holdings, Inc. $MRVI

General American Investors Co. Inc. raised its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 1,062.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,585,316 shares of the company’s stock after acquiring an additional 1,448,907 shares during the quarter. General American Investors Co. Inc. owned approximately 0.62% of Maravai LifeSciences worth $5,152,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Barclays PLC lifted its holdings in shares of Maravai LifeSciences by 3.0% during the fourth quarter. Barclays PLC now owns 172,281 shares of the company’s stock valued at $560,000 after acquiring an additional 5,057 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Maravai LifeSciences by 12.5% during the second quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock valued at $112,000 after acquiring an additional 5,160 shares during the period. Epacria Capital Partners LLC lifted its holdings in shares of Maravai LifeSciences by 6.8% during the third quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company’s stock valued at $287,000 after acquiring an additional 6,384 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Maravai LifeSciences by 121.1% during the second quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company’s stock valued at $43,000 after acquiring an additional 9,870 shares during the period. Finally, Sprott Inc. bought a new position in shares of Maravai LifeSciences during the third quarter valued at $29,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock opened at $4.98 on Friday. The stock has a 50-day simple moving average of $4.06 and a 200 day simple moving average of $3.65. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -7.01 and a beta of 0.72. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.99 and a 12-month high of $5.30.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. The firm had revenue of $65.84 million during the quarter, compared to analyst estimates of $53.00 million. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%. On average, research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MRVI. Wall Street Zen raised Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Weiss Ratings raised Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $6.00 price objective on shares of Maravai LifeSciences in a report on Friday, May 8th. UBS Group reissued a “reduce” rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Finally, Wells Fargo & Company lifted their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a report on Friday, May 8th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $5.50.

Insider Buying and Selling

In related news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total value of $126,500.00. Following the completion of the sale, the general counsel directly owned 360,767 shares in the company, valued at $1,825,481.02. This trade represents a 6.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by insiders.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.